BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 34884643)

  • 1. Humoral Predictors of Malignancy in IPMN: A Review of the Literature.
    Nista EC; Schepis T; Candelli M; Giuli L; Pignataro G; Franceschi F; Gasbarrini A; Ojetti V
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review.
    Ohno E; Balduzzi A; Hijioka S; De Pastena M; Marchegiani G; Kato H; Takenaka M; Haba S; Salvia R
    Pancreatology; 2024 Feb; 24(1):48-61. PubMed ID: 38161091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
    Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
    Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.
    Volckmar AL; Endris V; Gaida MM; Leichsenring J; Stögbauer F; Allgäuer M; von Winterfeld M; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Schirmacher P; Rudi J; Schmitz D; Stenzinger A
    Genes Chromosomes Cancer; 2019 Jan; 58(1):3-11. PubMed ID: 30230086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions.
    Das KK; Geng X; Brown JW; Morales-Oyarvide V; Huynh T; Pergolini I; Pitman MB; Ferrone C; Al Efishat M; Haviland D; Thompson E; Wolfgang C; Lennon AM; Allen P; Lillemoe KD; Fields RC; Hawkins WG; Liu J; Castillo CF; Das KM; Mino-Kenudson M
    Gastroenterology; 2019 Sep; 157(3):720-730.e2. PubMed ID: 31175863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the clinical utility of 4 guidelines in the initial triage of mucinous cystic lesions of the pancreas based on cross-sectional imaging: Experience with 188 surgically-treated patients.
    Park RHS; Lim GRS; Wu JJY; Koh YX; Teo JY; Cheow PC; Chan CY; Ooi LLPJ; Chung AYF; Goh BKP
    Eur J Surg Oncol; 2020 Nov; 46(11):2114-2121. PubMed ID: 32828582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts.
    Heidarian A; Das KK; Mino-Kenudson M; Fernandez-Del Castillo C; Pitman MB
    J Am Soc Cytopathol; 2021; 10(3):249-254. PubMed ID: 33541830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions.
    Wang J; Paris PL; Chen J; Ngo V; Yao H; Frazier ML; Killary AM; Liu CG; Liang H; Mathy C; Bondada S; Kirkwood K; Sen S
    Cancer Lett; 2015 Jan; 356(2 Pt B):404-9. PubMed ID: 25304377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Kucera S; Centeno BA; Springett G; Malafa MP; Chen YA; Weber J; Klapman J
    JOP; 2012 Jul; 13(4):409-13. PubMed ID: 22797397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraductal papillary mucinous neoplasm of the pancreas: Cytomorphology, imaging, molecular profile, and prognosis.
    Geramizadeh B; Marzban M; Shojazadeh A; Kadivar A; Maleki Z
    Cytopathology; 2021 Jul; 32(4):397-406. PubMed ID: 33792980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
    Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostaglandin E
    Yip-Schneider MT; Carr RA; Wu H; Schmidt CM
    J Am Coll Surg; 2017 Oct; 225(4):481-487. PubMed ID: 28739154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts.
    Matthaei H; Wylie D; Lloyd MB; Dal Molin M; Kemppainen J; Mayo SC; Wolfgang CL; Schulick RD; Langfield L; Andruss BF; Adai AT; Hruban RH; Szafranska-Schwarzbach AE; Maitra A
    Clin Cancer Res; 2012 Sep; 18(17):4713-24. PubMed ID: 22723372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Yamaue H
    Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance characteristics of molecular (DNA) analysis for the diagnosis of mucinous pancreatic cysts.
    Al-Haddad M; DeWitt J; Sherman S; Schmidt CM; LeBlanc JK; McHenry L; Coté G; El Chafic AH; Luz L; Stuart JS; Johnson CS; Klochan C; Imperiale TF
    Gastrointest Endosc; 2014 Jan; 79(1):79-87. PubMed ID: 23845445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
    Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
    Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.